Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics has revealed promising new data at the Society for Neuroscience 2024, demonstrating that its lead drug candidate, ATH434, offers neuroprotective benefits in treating neurodegenerative diseases like Parkinson’s. The studies show ATH434’s ability to reduce oxidative damage to neurons and improve mitochondrial energy production, which may slow disease progression. ATH434 is currently in Phase 2 clinical trials, bolstering hopes for its potential as a disease modifying treatment for Parkinsonian disorders.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
